Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis

What Was Tested

This randomized controlled trial paper looks at Goserelin in the context of endometriosis.

Who Took Part

The abstract describes 198 patients taking part.

PubMed indexes the participants as adults, women only.

A prospective cohort randomized study were conducted, including 198 patients diagnosed as having endometriosis.

A total of 111 patients were randomly assigned into two groups: the dienogest-administered group (n = 56) and the goserelin-administered group (n = 55).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.

A time span of 24 months appears in the methods.

Patients were followed for 24 months after laparoscopic surgery.

Those who gave consent but desired no postoperative therapy were assigned to the non-treatment group (n = 79).

Recurrence, side-effects, degrees of menstrual pain and chronic pelvic pain measured by the Visual Analogue Scale were compared among the three groups: the dienogest, goserelin, and non-treatment groups.

What Was Measured

PubMed files the paper under topics including Conservative Treatment, Endometriosis, Gonadotropin-Releasing Hormone, Goserelin, Hormone Antagonists, Nandrolone and Pain.

Author keywords: Visual Analogue Scale, dienogest, recurrence and surgery.

What This Means in Plain Language

The paper is a randomized study of Goserelin in 198 patients in people with endometriosis over 24 months.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (The journal of obstetrics and gynaecology research), a journal based in Australia.

More context: the Goserelin compound page, Endometriosis research.